Aigen Investment Management LP Makes New $407,000 Investment in RxSight, Inc. (NASDAQ:RXST)

Aigen Investment Management LP acquired a new position in RxSight, Inc. (NASDAQ:RXST) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,849 shares of the company’s stock, valued at approximately $407,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. RA Capital Management L.P. lifted its stake in shares of RxSight by 6.0% in the third quarter. RA Capital Management L.P. now owns 3,916,825 shares of the company’s stock worth $193,609,000 after buying an additional 222,000 shares during the last quarter. State Street Corp lifted its stake in shares of RxSight by 8.3% in the third quarter. State Street Corp now owns 817,671 shares of the company’s stock worth $40,417,000 after buying an additional 62,349 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of RxSight by 17.7% in the third quarter. Geode Capital Management LLC now owns 817,117 shares of the company’s stock worth $40,398,000 after buying an additional 122,775 shares during the last quarter. Brown Capital Management LLC acquired a new stake in shares of RxSight in the third quarter worth $26,813,000. Finally, Point72 Asset Management L.P. lifted its stake in shares of RxSight by 610.2% in the third quarter. Point72 Asset Management L.P. now owns 446,976 shares of the company’s stock worth $22,094,000 after buying an additional 384,041 shares during the last quarter. 78.78% of the stock is currently owned by institutional investors and hedge funds.

RxSight Price Performance

Shares of RxSight stock opened at $25.10 on Friday. The firm has a market capitalization of $1.02 billion, a PE ratio of -30.24 and a beta of 1.22. The company’s fifty day moving average price is $31.66 and its two-hundred day moving average price is $42.41. RxSight, Inc. has a 52-week low of $24.79 and a 52-week high of $66.54.

RxSight (NASDAQ:RXST) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.25). The business had revenue of $40.21 million during the quarter, compared to the consensus estimate of $40.23 million. RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. Analysts predict that RxSight, Inc. will post -0.7 earnings per share for the current fiscal year.

Insider Buying and Selling at RxSight

In other news, Director Shweta Maniar sold 3,519 shares of the company’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $30.87, for a total value of $108,631.53. Following the sale, the director now owns 7,383 shares of the company’s stock, valued at approximately $227,913.21. This represents a 32.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jesse Anderson Corley bought 1,443 shares of the stock in a transaction dated Wednesday, January 15th. The stock was purchased at an average cost of $31.18 per share, for a total transaction of $44,992.74. Following the acquisition, the director now owns 1,443 shares in the company, valued at $44,992.74. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders own 9.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Stifel Nicolaus reduced their price objective on shares of RxSight from $35.00 to $33.00 and set a “hold” rating for the company in a research note on Wednesday, February 26th. Wells Fargo & Company cut their target price on shares of RxSight from $40.00 to $35.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 26th. UBS Group began coverage on shares of RxSight in a research note on Friday, December 6th. They set a “buy” rating and a $52.00 target price for the company. JPMorgan Chase & Co. cut their target price on shares of RxSight from $62.00 to $40.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $43.00 target price on shares of RxSight in a research note on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.63.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.